MIND C.T.I. Ltd (MNDO) Is At $2.81 Formed Wedge; Dicerna Pharmaceuticals (DRNA) Shorts Raised By 23.45%

Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) had an increase of 23.45% in short interest. DRNA’s SI was 458,500 shares in February as released by FINRA. Its up 23.45% from 371,400 shares previously. With 240,700 avg volume, 2 days are for Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA)’s short sellers to cover DRNA’s short positions. The SI to Dicerna Pharmaceuticals Incorporated’s float is 3.66%. The stock increased 2.09% or $0.2 during the last trading session, reaching $9.79. About 266,734 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since February 2, 2017 and is downtrending. It has underperformed by 21.92% the S&P500.

MIND C.T.I. Ltd (MNDO) formed wedge up with $3.03 target or 8.00% above today’s $2.81 share price. MIND C.T.I. Ltd (MNDO) has $54.14 million valuation. The stock increased 0.24% or $0.0066 during the last trading session, reaching $2.8066. About 10,149 shares traded. MIND C.T.I. Ltd (NASDAQ:MNDO) has risen 21.75% since February 2, 2017 and is uptrending. It has outperformed by 5.05% the S&P500.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $505.57 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Investors sentiment increased to 0.79 in Q3 2017. Its up 0.24, from 0.55 in 2017Q2. It is positive, as 9 investors sold Dicerna Pharmaceuticals, Inc. shares while 10 reduced holdings. 8 funds opened positions while 7 raised stakes. 10.37 million shares or 6.06% less from 11.04 million shares in 2017Q2 were reported. Virtu Limited Co holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 19,861 shares. Palo Alto Investors Llc owns 500,913 shares or 0.12% of their US portfolio. Bourgeon Mngmt Limited Liability Corp reported 33,000 shares. Dimensional Fund Limited Partnership holds 27,342 shares or 0% of its portfolio. Blackrock Inc holds 0% or 113,396 shares in its portfolio. 51,681 are owned by Deutsche Commercial Bank Ag. Goldman Sachs Inc, a New York-based fund reported 105,420 shares. Bridgeway Mngmt Inc has 0.01% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 168,300 shares. Bnp Paribas Arbitrage accumulated 0% or 32 shares. 683 Capital Mngmt Limited Liability holds 0.46% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 760,233 shares. Connor Clark & Lunn Invest Mngmt holds 68,975 shares. The Massachusetts-based Fmr Ltd Llc has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Art Limited Com reported 17,650 shares stake. Geode Capital Mgmt Ltd Liability Com owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 91,737 shares. Bancshares Of Mellon holds 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 28,564 shares.

Since December 18, 2017, it had 1 buying transaction, and 0 insider sales for $2.00 million activity. 285,000 shares valued at $2.00 million were bought by Bain Capital Life Sciences Investors – LLC on Monday, December 18.